Guideline
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
- PMID: 14520607
Item in Clipboard
Guideline
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
Am J Kidney Dis.
2003 Oct.
No abstract available
Comment in
-
Clinical significance of the K/DOQI bone guidelines in Japan.Am J Kidney Dis. 2004 Aug;44(2):383-4; author reply 384. doi: 10.1053/j.ajkd.2004.05.038. Am J Kidney Dis. 2004. PMID: 15264200 No abstract available.
-
Relevance of aluminum screening in 2006.Am J Kidney Dis. 2006 Jul;48(1):182; author reply 182. doi: 10.1053/j.ajkd.2006.04.088. Am J Kidney Dis. 2006. PMID: 16797406 No abstract available.
Similar articles
-
Guidelines for disorders of mineral metabolism and secondary hyperparathyroidism should not yet be modified.Nat Clin Pract Nephrol. 2006 Jun;2(6):337-9. doi: 10.1038/ncpneph0190. Nat Clin Pract Nephrol. 2006. PMID: 16932455
-
Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients.Nat Clin Pract Nephrol. 2006 Jun;2(6):326-36. doi: 10.1038/ncpneph0189. Nat Clin Pract Nephrol. 2006. PMID: 16932454
-
K/DOQI guidelines released on bone metabolism and disease in CKD.Nephrol News Issues. 2003 Nov;17(12):38-41, 44. Nephrol News Issues. 2003. PMID: 14640009 No abstract available.
-
[K/DOQI clinical practice guidelines for bone metabolism and disease in CKD].Clin Calcium. 2004 Sep;14(9):9-14. Clin Calcium. 2004. PMID: 15577103 Review. Japanese.
-
Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines.Kidney Int Suppl. 2005 Jul;(96):S7-14. doi: 10.1111/j.1523-1755.2005.00449.x. Kidney Int Suppl. 2005. PMID: 15954948 Review.
Cited by
-
Fracture Risk in Patients on Hemodialysis: the Lower the Parathyroid Hormone the Better?Kidney Int Rep. 2024 Aug 29;9(10):2854-2856. doi: 10.1016/j.ekir.2024.08.023. eCollection 2024 Oct. Kidney Int Rep. 2024. PMID: 39430190 Free PMC article. No abstract available.
-
Evidence in chronic kidney disease-mineral and bone disorder guidelines: is it time to treat or time to wait?Clin Kidney J. 2020 Jan 25;13(4):513-521. doi: 10.1093/ckj/sfz187. eCollection 2020 Aug. Clin Kidney J. 2020. PMID: 32905295 Free PMC article. Review.
-
Hyperphosphatemia Management in Patients with Chronic Kidney Disease.Saudi Pharm J. 2016 Jul;24(4):494-505. doi: 10.1016/j.jsps.2015.01.009. Epub 2015 Jan 12. Saudi Pharm J. 2016. PMID: 27330380 Free PMC article. Review.
-
Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled.Int Urol Nephrol. 2012 Dec;44(6):1731-44. doi: 10.1007/s11255-012-0271-4. Epub 2012 Sep 11. Int Urol Nephrol. 2012. PMID: 22965378 Review.
-
Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease.Int J Biol Sci. 2012;8(5):663-71. doi: 10.7150/ijbs.3886. Epub 2012 May 5. Int J Biol Sci. 2012. PMID: 22606047 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
